Drugs / Elacytarabine
Elacytarabine
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01783964 | Feb 2013 | — | Clavis Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01258816 | Oct 2010 → May 2013 | acute myeloid leukemia | Clavis Pharma | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00831636 | Apr 2008 → Nov 2009 | ovarian cancer | Clavis Pharma | Completed | No outcome recorded |
| Phase 1/2 | NCT00405743 | May 2006 → May 2009 | acute myeloid leukemia | Clavis Pharma | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01035502 | Dec 2009 → May 2013 | acute myeloid leukemia | Clavis Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00498407 | May 2007 → Dec 2008 | colorectal cancer | Clavis Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00498836 | Mar 2007 → Oct 2008 | melanoma | Clavis Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00232726 | Sep 2005 → Jul 2007 | melanoma, metastatic neoplasm | Clavis Pharma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01147939 | Jun 2010 → Feb 2013 | acute myeloid leukemia | Clavis Pharma | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elacytarabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01147939 ↗ |
| Known as | [14C]-Elacytarabine | “An Open-Label, Single-Dose Study Designed to Assess the Mass Balance Recovery of an Intravenous Microdose of [14C]-Elacytarabine in Healthy Male Subjects” NCT01783964 ↗ |
| Known as | CP-4055 | “Elacytarabine (CP-4055) is a pro-drug of ara-C currently used in the treatment of patients with acute myeloid leukaemia.” NCT01035502 ↗ |
| Known as | Cytarabine eliadate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105665 ↗ |
| Known as | Elacitarabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105665 ↗ |
| Known as | ELACYT | “CP-4055 (ELACYT)” NCT00232726 ↗ |
| Known as | P-4055 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105665 ↗ |
| Modality | Small molecule | “Elacytarabine is the elaidic acid ester derivative of cytarabine, designed to enter cells independently of nucleoside transporters.” PMID 24433865 ↗ Dec 2013 |
| Route | Intravenous | “CP-4055 is given intravenously on days 1-5 every four weeks until complete response or disease progression.” NCT00232726 ↗ |